Does PRALSETINIB Cause Carcinoembryonic antigen increased? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Carcinoembryonic antigen increased have been filed in association with PRALSETINIB (Gavreto). This represents 0.5% of all adverse event reports for PRALSETINIB.
7
Reports of Carcinoembryonic antigen increased with PRALSETINIB
0.5%
of all PRALSETINIB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Carcinoembryonic antigen increased From PRALSETINIB?
Of the 7 reports, 1 (14.3%) required hospitalization.
Is Carcinoembryonic antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PRALSETINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does PRALSETINIB Cause?
Death (126)
Fatigue (104)
Asthenia (96)
Off label use (92)
Hypertension (89)
Disease progression (85)
Anaemia (80)
Diarrhoea (79)
Pyrexia (75)
White blood cell count decreased (74)
What Other Drugs Cause Carcinoembryonic antigen increased?
RIBOCICLIB (143)
LETROZOLE (115)
CAPECITABINE (113)
FULVESTRANT (105)
BEVACIZUMAB (102)
REGORAFENIB (91)
OXALIPLATIN (88)
OSIMERTINIB (82)
PALBOCICLIB (78)
FLUOROURACIL (71)
Which PRALSETINIB Alternatives Have Lower Carcinoembryonic antigen increased Risk?
PRALSETINIB vs PRAMIPEXOLE
PRALSETINIB vs PRAMIPEXOLE\PRAMIPEXOLE
PRALSETINIB vs PRAMLINTIDE
PRALSETINIB vs PRASTERONE
PRALSETINIB vs PRASUGREL